Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 1, 2011, Pages 160-170

  Brain, Etienne G C ^a,b   Mertens, Cécile ^c   Girre, Véronique ^a   Rousseau, Frédérique ^d   Blot, Emmanuel ^e   Abadie, Sophie ^f   Uwer, Lionel ^g   Bourbouloux, Emmanuelle ^h   Van Praagh Doreau, Isabelle ⁱ   Mourey, Loic ^j   Kirscher, Sylvie ^k   Laguerre, Brigitte ^l   Fourme, Emmanuelle ^a   Luneau, Sylvia ^a,m   Genève, Jean ^b   Debled, Marc ^c  

^a INSTITUT CURIE   (France)

^b FNCLCC   (France)

^c INSTITUT BERGONIÉ   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e CENTRE HENRI BECQUEREL   (France)

^f CENTRE PAUL PAPIN   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ CENTRE JEAN PERRIN   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k INSTITUT SAINTE CATHERINE   (France)

^l CENTRE EUGÈNE MARQUIS   (France)

^m Clinique de la Porte Verte   (France)

more..

Author keywords

Adjuvant; Anthracyclines; Breast carcinoma; Chemotherapy; Comprehensive geriatric assessment; Elderly; Functional status; Nonpegylated liposomal doxorubicin; Nutritional status

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANISETRON; HORMONE RECEPTOR; ONDANSETRON;

AGED; ANEMIA; ANOREXIA; ARTHRITIS; BLOOD TOXICITY; BONE PAIN; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; COGNITION; COMORBIDITY; DAILY LIFE ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; EARLY CANCER; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FRANCE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INJECTION SITE REACTION; MALNUTRITION; MENTAL HEALTH; MINI NUTRITIONAL ASSESSMENT; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA AND VOMITING; NEUTROPENIA; PALMOPLANTAR DYSAESTHESIA; PATIENT AUTONOMY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; REVIEW; SENSORY DYSFUNCTION; SOCIAL INTERACTION; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; GERIATRIC ASSESSMENT; HUMANS; PERSONAL AUTONOMY; QUALITY OF LIFE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 80053130297     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.10.003     Document Type: Review

References (56)

1. Giannakouris K. Ageing characterises the demographic perspectives of the European societies. Population and social conditions. Eurostat Stat Focus 2010, 72/2008. http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-08-072/EN/KS-SF-08-072-EN.PDF.
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592.
3. Horner M.J., Ries L.A.G., Krapcho M., et al. SEER Cancer Statistics Review 1975-2006 2010, National Cancer Institute, Bethesda, MD.
4. Daidone M.G., Coradini D., Martelli G., Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 2003, 45(3):313-325.
5. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8(12):1101-1115.
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
7. Berry D.A, Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295(14):1658-1667.
8. Elkin E.B., Hurria A., Mitra N., Schrag D., Panageas K.S. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006, 24(18):2757-2764.
9. Giordano S.H., Duan Z., Kuo Y.F., Hortobagyi G.N., Goodwin J.S. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006, 24(18):2750-2756.
10. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97(11):2869-2879.
11. Fargeot P., Bonneterre J., Roche H., et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004, 22(23):4622-4630.
12. Batist G., Ramakrishnan G., Rao C.S., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19(5):1444-1454.
13. Chan S., Davidson N., Juozaityte E., et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004, 15(10):1527-1534.
14. Biganzoli L., Coleman R., Minisini A., et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007, 61(1):84-89.
15. Coleman R.E., Biganzoli L., Canney P., et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006, 42(7):882-887.
16. Hurria A., Lachs M.S., Cohen H.J., Muss H.B., Kornblith A.B. Geriatric assessment for oncologists: rationale and future directions. Crit Rev Oncol Hematol 2006, 59(3):211-217.
17. Dempster M., Donnelly M. How well do elderly people complete individualised quality of life measures: an exploratory study. Qual Life Res 2000, 9(4):369-375.
18. Kendal W.S. Dying with cancer: the influence of age, comorbidity, and cancer site. Cancer 2008, 112(6):1354-1362.
19. Satariano W.A., Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994, 120(2):104-110.
20. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55(3):241-252.
21. Katz S., Downs T.D., Cash H.R., Grotz R.C. Progress in development of the index of ADL. Gerontologist 1970, 10(1):20-30.
22. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9(3):179-186.
23. Guigoz Y., Vellas B.J. [Malnutrition in the elderly: the Mini Nutritional Assessment (MNA)]. Ther Umsch 1997, 54(6):345-350.
24. Tombaugh T.N., McIntyre N.J. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992, 40(9):922-935.
25. Roberts R.E., Vernon S.W. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry 1983, 140(1):41-46.
26. Miller M.D., Paradis C.F., Houck P.R., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992, 41(3):237-248.
27. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376.
28. Extermann M., Albrand G., Chen H., et al. Are older French patients as willing as older American patients to undertake chemotherapy?. J Clin Oncol 2003, 21(17):3214-3219.
29. Lindley C., Vasa S., Sawyer W.T., Winer E.P. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998, 16(4):1380-1387.
30. Mandelblatt J.S., Hadley J., Kerner J.F., et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 2000, 89(3):561-573.
31. Repetto L., Carreca I., Maraninchi D., Aapro M., Calabresi P., Balducci L. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 2003, 45(2):123-128.
32. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43(2):258-270.
33. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42(15):2433-2453.
34. Abetz L., Coombs J.H., Keininger D.L., et al. Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing. Value Health 2005, 8(Suppl. 1):S41-S53.
35. Balducci L., Ershler W.B. Cancer and ageing: a nexus at several levels. Nat Rev Cancer 2005, 5(8):655-662.
36. Muss H.B., Berry D.A., Cirrincione C.T., et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360(20):2055-2065.
37. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 2008, 26(8):1201-1203.
38. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342(15):1077-1084.
39. Piccirillo J.F., Vlahiotis A., Barrett L.B., Flood K.L., Spitznagel E.L., Steyerberg E.W. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008, 67(2):124-132.
40. Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25(25):3808-3815.
41. van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006, 4:CD005006.
42. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008, 2:CD003917.
43. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007, 14(1):7-12.
44. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 20(2):494-502.
45. Blanc-Bisson C., Fonck M., Rainfray M., Soubeyran P., Bourdel-Marchasson I. Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol 2008, 67(3):243-254.
46. Soubeyran P., Bellera C.A., Gregoire F., et al. Validation of a screening test for elderly patients in oncology. J Clin Oncol 2008, 26(15S).
47. McCorkle R., Strumpf N.E., Nuamah I.F., et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 2000, 48(12):1707-1713.
48. Collins B., Mackenzie J., Stewart A., Bielajew C., Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009, 18(2):134-143.
49. Hurria A., Goldfarb S., Rosen C., et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 2006, 98(3):343-348.
50. Hurria A., Lachs M. Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer?. Breast Cancer Res Treat 2007, 103(3):259-268.
51. Meyers C.A., Byrne K.S., Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995, 12(3):231-235.
52. Sprangers M.A., Groenvold M., Arraras J.I., et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996, 14(10):2756-2768.
53. Gelber R.D., Goldhirsch A., Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 1991, 114(8):621-628.
54. Browall M.M., Ahlberg K.M., Persson L.O., Karlsson P.O., Danielson E.B. The impact of age on Health-Related Quality of Life (HRQoL) and symptoms among postmenopausal women with breast cancer receiving adjuvant chemotherapy. Acta Oncol 2008, 47(2):207-215.
55. Fitzsimmons D., Gilbert J., Howse F., et al. A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. Eur J Cancer 2009, 45(1):19-32.
56. Valero V., Buzdar A.U., Theriault R.L., et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999, 17(5):1425-1434.